Med 11 AG
MED-11 AG ANNOUNCES INTENTION TO SPLIT INTO TWO SEPARATE COMPANIES
Med 11 AG / Strategic Company Decision Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- MED-11 AG ANNOUNCES INTENTION TO SPLIT INTO TWO SEPARATE COMPANIES ZUG, Switzerland, May 7, 2008 – Swiss-based MED-11 AG, Frankfurt Stock Exchange (WKN: A0LGDQ) will be seeking shareholder approval at its annual general meeting in July 2008, to separate the Diagnostic Division and the Nutraceutical Division into two separate companies. Management is initiating this corporate restructuring as it believes MED-11 AG’s current valuation does not reflect the inherent value of the progress made towards commercialization of the world’s first lung cancer screening test. Shareholders will receive one share in the new company, MED-DIA SYSTEMS AG, for free for every MED-11 AG share held and registered with the Company at the time of the split. MED-DIA SYSTEMS AG will be responsible for the commercialization of the 'Cancer Screening Tests' and will focus on developing medical devices for the detection and diagnosis of disease. MED-DIA SYSTEMS AG will oversee the FDA regulated Clinical Trials for Lung Screen Plus, the lung cancer screening test, and will submit applications to the FDA to commercialize MED-11 AG’s breast and colon cancer screening tests. MED-11 AG will continue to focus on the world’s fastest-growing medical specialty, anti-aging medicine, and the retail distribution of its product line. Management intends to list MED-DIA SYSTEMS AG on the Frankfurt Stock Exchange once FDA approval has been granted to commercialize Lung Screen Plus. FDA approval is expected before the second quarter of 2009. About MED-11 (www.med-11.ch, www.med-11diagnostic.com and www.med-11.com) MED-11 AG is medical service company with a wide range of patented medical products in different market segments. These include Cancer Screening Tests, Cancer Preventive Dietary Supplements; Personal Care Products; and prepackaged Modular Medical Clinics. The Company identified ‘medical diagnostics’ and ‘preventive health care’ as sectors of the medical service industry that were experiencing strong growth. As a result of management’s background and experience in the United States pharmaceutical, nutraceutical and retail industry, MED-11 made several investments and acquired the United States and Japanese patents to, Screening Tests for Colon Cancer, Lung Cancer and Breast Cancer; the worldwide Licenses to manufacture and distribute certain Cancer Preventive Dietary Supplements; the worldwide Licenses to manufacture and distribute Modular Medical Clinics; and distribution agreements for various Personal Care Nutraceutical Products. Through the provision, by Medical Practioners, of evidence-based clinical proof of each products safety and efficacy, the Company aims to acquire a major position in this expanding market. For further information contact: Ulrike Dickmann, Investor Relations: Phone: +49-1577-631-55-88 or Email: u.dickmann@med-11diagnostics.com or Mail to: MED-11 AG, Alpenstrasse 7, CH-6300, Zug, Switzerland. 07.05.2008 Financial News transmitted by DGAP ----------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden